Comprehensive docking and refinement of human glutaminyl cyclase inhibitors for the drug discovery of alzheimer’s disease

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: CHOI, Sun (Ewha Womans University, Korea, Republic Of)
  • Co-author(s): Sun Choi:
    Minghua Cui: College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea, Republic Of
    Jongmi Park: College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea, Republic Of
    Jeewoo Lee: College of Pharmacy, Seoul National University, Seoul, Korea, Republic Of
  • Abstract:

    Background

    Glutaminyl cyclase (QC) is an enzyme catalyzing the N-terminal modification of glutamyl or glutaminyl precursors into pyroglutamate. The formation of pyroglutamate-modified Aβ peptide triggers the accumulation of Aβ oligomer and proto-fibrils causing neurotoxicity like brain cell death.

    Purpose

    Since these toxic materials aggravate..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login